Table 1 Properties of proteasome inhibitors and clinical administration route
From: Proteasome inhibitors as experimental therapeutics of autoimmune diseases
Proteasome inhibitor | Class | Target(s) | Administration route |
|---|---|---|---|
MG-132 | Aldehyde | CP and IP | Not known |
Bortezomib | Boronate | CP and IP | Intravenous/subcutaneous |
Carfilzomib (PR-171) | α’,β’-Epoxyketone | CP and IP | Intravenous |
Delanzomib (CEP-18770/cephalon) | Boronate | CP and IP | Oral |
ONX 0912 (PR-047/oprozomib) | α’,β’-Epoxyketone | CP and IP | Oral |
ONX 0914 (PR-957) | α’,β’-Epoxyketone | IP | Intravenous |
MLN9708* (ioxazomib): hydrolizes to MLN2238 | Boronate | CP and IP | Oral |
Marizomib* (NPI-0052/salinosporamide A) | β-Lactone | CP and IP | Intravenous and oral |
PR-924* (IPSI) | α’,β’-Epoxyketone | IP | Intravenous |